Colorado State University
Goodrich Lab at Colorado State University focuses on research for treating and preventing disease transmission, with emphasis on vaccine development and pathogen inactivation using photochemical methods. The lab conducts both fundamental and translational research ranging from device prototyping and animal studies to clinical trial readiness. Disease targets include SARS-CoV-2, tuberculosis, various strains of influenza, African swine fever, and cancer immunotherapy.
Industries
N/A
Nr. of Employees
small (1-50)
Colorado State University
Office: D210, Colorado State University
Products
Vaccine candidates for infectious diseases
Vaccine formulations developed for diseases such as SARS-CoV-2, human and avian influenza, tuberculosis, and African swine fever, designed and tested in various animal models.
Photochemical devices for pathogen inactivation and vaccine manufacturing
Prototype devices enabling photochemical inactivation of pathogens in blood products and large-scale vaccine batch processing.
Cancer immunotherapy approach using light-inactivated tumor cells
Experimental immunotherapy strategy using whole, light-inactivated tumor cells derived from the patient to stimulate an immune response against cancer.
Vaccine candidates for infectious diseases
Vaccine formulations developed for diseases such as SARS-CoV-2, human and avian influenza, tuberculosis, and African swine fever, designed and tested in various animal models.
Photochemical devices for pathogen inactivation and vaccine manufacturing
Prototype devices enabling photochemical inactivation of pathogens in blood products and large-scale vaccine batch processing.
Cancer immunotherapy approach using light-inactivated tumor cells
Experimental immunotherapy strategy using whole, light-inactivated tumor cells derived from the patient to stimulate an immune response against cancer.
Expertise Areas
- Vaccine development
- Pathogen inactivation
- Transfusion medicine
- Animal model studies
Key Technologies
- Photochemical inactivation
- Vaccine formulation
- Animal model testing
- GMP manufacturing
News & Updates
Socks Jones of the Goodrich Lab won second place for his foundational research poster at CSU Research Day 2026.
Coverage on new clinical trial of light-inactivated tumor cell immunotherapy led by Dr. Ray Goodrich.
Development of cancer immunotherapy using patient’s tumor cells to train the immune system by Dr. Raymond Goodrich.
Team led by Dr. Ray Goodrich gets approval to begin human trials on a new cancer immunotherapy.
Features the team’s work on personalized immunotherapy for ovarian cancer patients.
Lab develops new immunotherapy approach to treat cancer.
Socks Jones of the Goodrich Lab won second place for his foundational research poster at CSU Research Day 2026.
Coverage on new clinical trial of light-inactivated tumor cell immunotherapy led by Dr. Ray Goodrich.
Development of cancer immunotherapy using patient’s tumor cells to train the immune system by Dr. Raymond Goodrich.
Team led by Dr. Ray Goodrich gets approval to begin human trials on a new cancer immunotherapy.
Features the team’s work on personalized immunotherapy for ovarian cancer patients.
Lab develops new immunotherapy approach to treat cancer.